Pfizer Cash and Equivalents

PFE
 Stock
  

USD 52.31  0.12  0.23%   

Pfizer Inc fundamentals help investors to digest information that contributes to Pfizer's financial success or failures. It also enables traders to predict the movement of Pfizer Stock. The fundamental analysis module provides a way to measure Pfizer's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pfizer stock. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Refresh
The current year Cash and Equivalents is expected to grow to about 2.7 B. The current year Cash and Equivalents Turnover is expected to grow to 47.05.

Pfizer Cash and Equivalents Analysis

Pfizer's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Pfizer Cash and Equivalents

2.71 Billion

Share
Cash 
 = 
Bank Deposits 
+  
Liquidities 
More About Cash and Equivalents | All Equity Analysis

Current Pfizer Cash and Equivalents

    
  23.9 B  
Most of Pfizer's fundamental indicators, such as Cash and Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pfizer Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Pfizer Cash and Equivalents Historical Pattern

Today, most investors in Pfizer Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pfizer's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash and equivalents growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Pfizer cash and equivalents as a starting point in their analysis.
 Pfizer Cash and Equivalents 
Share
      Timeline 
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Compare to competition

In accordance with the recently published financial statements, Pfizer Inc has 23.9 B in Cash and Equivalents. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The cash and equivalents for all United States stocks is significantly lower than that of the firm.

Pfizer Cash and Equivalents Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pfizer's direct or indirect competition against its Cash and Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pfizer could also be used in its relative valuation, which is a method of valuing Pfizer by comparing valuation metrics of similar companies.
Pfizer is currently under evaluation in cash and equivalents category among related companies.

Pfizer Current Valuation Drivers

We derive many important indicators used in calculating different scores of Pfizer from analyzing Pfizer's financial statements. These drivers represent accounts that assess Pfizer's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Pfizer's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee236.23 K120.7 K184.29 K122.16 K278.23 K300.19 K
Revenue Per Employee582.55 K580.6 K586.07 K532.4 K1.03 M1.11 M
Average Assets170.91 B170.32 B164.21 B162.39 B146.15 B149.93 B
Earnings Before Interest Taxes and Depreciation Amortization EBITDA17.94 B17.76 B23.64 B12.31 B29.27 B23.13 B
Earnings Before Interest Taxes and Depreciation Amortization USD14.1 B18.53 B18.24 B23.67 B21.3 B19.62 B
Earnings before Tax8.34 B12.26 B11.86 B17.66 B20.31 B18.49 B
Average Equity62.17 B62.22 B68.67 B61.66 B55.49 B59.93 B
Enterprise Value239.08 B257.07 B289.8 B266.7 B306.71 B295.03 B
Free Cash Flow14.19 B14.59 B13.63 B9.99 B8.99 B10.72 B
Invested Capital72.89 B78.83 B79.54 B87.01 B78.31 B80.24 B
Invested Capital Average79.13 B77.76 B73.71 B84.26 B75.84 B79.17 B
Market Capitalization197.1 B215.9 B252.32 B216.83 B249.35 B242.51 B
Tangible Asset Value64.52 B67.1 B70.8 B73.47 B66.12 B70.04 B
Working Capital7.83 B10.71 B18.07 B(4.5 B)(4.05 B)(4.16 B)

Pfizer Fundamentals

About Pfizer Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Cash and Equivalents1.9 B2.7 B
Cash and Equivalents Turnover 43.61  47.05 
Free Cash FlowB10.7 B
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 79000 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Pfizer without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Global Markets Map Now

   

Global Markets Map

Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
All  Next Launch Module

Currently Active Assets on Macroaxis

Please check Pfizer Piotroski F Score and Pfizer Altman Z Score analysis. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for Pfizer Stock analysis

When running Pfizer Inc price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.59
Market Capitalization
293.5 B
Quarterly Revenue Growth YOY
0.77
Return On Assets
0.12
Return On Equity
0.34
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine Pfizer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.